October 22, 2018
FDA Approves Vizimpro for EGFR-Mutated Non-Small Cell Lung Cancer BookmarkEmma Shtivelman, PhD
Excerpt from Healio:
“The FDA approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletion or exon 21 L858R substitution mutations.
“Dacomitinib (Vizimpro, Pfizer) is a once-daily oral pan-human EGFR tyrosine kinase inhibitor.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.